Logo

Samsung Bioepis Highlights 2 Abstracts for SB17 (biosimilar, ustekinumab) for the Treatment of Moderate-to-Severe Psoriasis at ECCO 2024

Share this

Samsung Bioepis Highlights 2 Abstracts for SB17 (biosimilar, ustekinumab) for the Treatment of Moderate-to-Severe Psoriasis at ECCO 2024

Shorts:  

  • The first study highlights the analytical assessment results of SB17 vs Stelara (ustekinumab) which demonstrated on SB17 to biologically similar to Stelara in terms of its physicochemical, structural & biological attributes 
  • Additionally, the data supports the similarity of SB17 with reference Stelara in terms of the biosimilarity, PK, PD, clinical effect in patients suffering from moderate-to-severe psoriasis  
  • Samsung Bioepis has recently signed a collaborative agreement with Sandoz to commercialize SB17 across the US, EU, UK, Canada & Switzerland

Ref: Samsung Bioepis | Image: Samsung Bioepis

Related News:- Samsung Bioepis Successfully Resolves Patent Disputes with Johnson & Johnson

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.comSamsung Bioepis, SB17, Ustekinumab, Crohn's diseases, Biosimilar, Partnership, Switzerland, Canada, EU, US, ECCO

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions